The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases.
about
The clinical relevance of autoantibodies in sclerodermaThe use of laboratory tests in the diagnosis of SLECaesarean section in a case of systemic lupus erythematosus.Methodological issues of corticosteroid use in SLE clinical trials.Antiphospholipid antibodies predict progression of abdominal aortic aneurysmsAntiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report.Cerebral venous thrombosis presenting with subdural haematoma as first presentation for systemic lupus erythematosus with negative antiphospholipid antibodies.Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy.Lower extremity ulcers in systemic sclerosis: features and response to therapy.Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohortThe coexistence of antiphospholipid syndrome and systemic lupus erythematosus in ColombiansAntiphospholipid syndrome: an overview.Autoantibodies and thrombophilia in RA: TNFalpha and TNFalpha blockers.Prevalence of the antiphospholipid syndrome in primary systemic vasculitisPulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction.Antiphospholipid-related chorea.Primary systemic vasculitis: treatment of difficult cases.Autoantibody determination in the diagnosis of systemic lupus erythematosus.Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus.A case of Churg-Strauss syndrome associated with antiphospholipid antibodiesA novel overlap syndrome: systemic sclerosis associated with antiphospholipid syndrome--a case series.Anticardiolipin antibodies in proliferative diabetic retinopathy: An additional risk factor.Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients.Diagnostic algorithm for Raynaud's phenomenon and vascular skin lesions in systemic lupus erythematosus.Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies.The emerging role of multiple antiphospholipid antibodies positivity in patients with antiphospholipid syndrome.Anti-Jo-1 myositis and the antiphospholipid syndrome showing right ventricular thrombus: a novel overlap syndrome with atypical presentation.Antiphospholipid antibodies in thromboangiitis obliterans.Adrenal gland abnormalities detected by magnetic resonance imaging in patients with antiphospholipid syndrome.Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis.Severe digital ischemia-a presenting symptom of malignancy-associated antiphospholipid syndrome.Dermatomyositis and polymyositis associated with the antiphospholipid syndrome-a novel overlap syndrome.Pulmonary hypertension associated with antiphospholipid antibody: Call for a screening tool?Prevalence and isotype distribution of antiphospholipid antibodies in Chilean patients with systemic lupus erythematosus (SLE).Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype.Antiphospholipid antibodies in patients with purported 'chronic Lyme disease'.A case of Churg-Strauss syndrome with visual loss following central retinal artery occlusion.Atypical presentation of scleroderma in infancy.A 66-Year-Old Woman With Hemoptysis.Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis
P2860
Q24682842-3F542475-102C-4E70-8013-724C95C72360Q24682977-79FB4EB7-6D1F-4C3A-AECB-B18B28CD9438Q33731619-DB463A4E-1F17-4957-808C-B29AB110A81BQ33777440-534DE60E-4B40-48B7-B257-E2FBFF2029F4Q33825446-122BF0D1-B6BA-43AA-9332-AF2E37DFB043Q33944344-D23F179D-EE56-462C-82DF-0C209F4BBF5DQ33994624-F188142F-6099-4615-899B-D1D269867C1DQ34106037-8195B376-B5F3-4828-94C9-54533829B1E0Q34106172-5B52595D-41B1-44D0-A715-7FF7BF6F8FE5Q34161393-E305090D-78E5-4109-B6B3-21AC93E7D7E3Q34400681-80AFF518-EE44-4613-87F5-8D8853BE01ACQ35099505-72449EFA-6862-41C6-87DB-83B674246EE5Q35554200-DCEDA978-80C9-468F-AF1B-0AF26C7CEE45Q35636529-799C00E1-5CA1-430F-9623-3A2B08FFF6AEQ35867030-93B3C2BF-B997-4EC0-803C-689D46DC5961Q36337350-1DA8C694-9763-4A3A-9E69-388B62FAE67FQ36458145-E86708EA-A039-4F67-A5D0-50359656EB6AQ36570675-E4E07B33-276A-46EC-B84A-3D591D0B130DQ36709341-F3BEC232-7B5E-4C95-A70F-10B4819FEA8EQ36950708-4A750EA6-BF65-4981-A8F2-E2351E4407F9Q36951073-4552BAC1-F67D-409A-9220-F07BECD34EA7Q37059992-9DA90975-53E4-4455-98AB-6AA7B4FB0D89Q37351603-1E27C26A-4069-400C-9DA2-8D63864532D1Q37778648-7BC09F41-A595-4D2C-92B4-C6F3826B320DQ38113521-0DAF72F4-A24C-4B37-9046-D4A724FB954CQ38570944-8DC9BB24-3A6F-4C6D-99EE-1C3594CF72B4Q39572709-733686B5-82B1-448C-839F-860042DAA923Q39647780-EC177BF8-E497-4B74-BE88-914EECD52D2AQ39680327-2D2362B2-D410-4D10-AFA6-89BD96997D1AQ39822565-FDBFC308-0EF2-417B-AEB8-24277673A9DFQ39841022-D6E0BD5E-DC69-409B-8053-4A23BB4CFB47Q40774311-EB6617FC-820B-4308-BD80-6362FF679AADQ41700174-AB921534-E524-4E61-9C16-C17470BBA790Q43677862-9F413FB6-E3A4-4946-AFC0-3CFE5DD2099CQ43850415-729648D2-6EF0-47D0-9642-5468F48630D6Q44281373-B443D0F1-81F7-44AC-9C72-82FAAEF32EF2Q45307620-BF526F31-5D38-4E85-BD90-8B4A81F0B237Q51503752-23F493D6-6E17-46AD-BF7C-228699B9FA92Q55070916-4982B167-27EF-4525-92CC-B51F93E645A5Q57602063-D5347183-FA26-44C7-BBB4-6927FE0999CA
P2860
The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases.
description
1996 nî lūn-bûn
@nan
1996 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
The prevalence and clinical as ...... th connective tissue diseases.
@ast
The prevalence and clinical as ...... th connective tissue diseases.
@en
type
label
The prevalence and clinical as ...... th connective tissue diseases.
@ast
The prevalence and clinical as ...... th connective tissue diseases.
@en
prefLabel
The prevalence and clinical as ...... th connective tissue diseases.
@ast
The prevalence and clinical as ...... th connective tissue diseases.
@en
P2093
P1476
The prevalence and clinical as ...... th connective tissue diseases.
@en
P2093
Pierangeli SS
Polisson RP
P304
P356
10.1016/S0002-9343(96)00335-X
P407
P577
1996-12-01T00:00:00Z